You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CARFILZOMIB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Carfilzomib, and when can generic versions of Carfilzomib launch?

Carfilzomib is a drug marketed by Apotex, Breckenridge, and Dr Reddys. and is included in four NDAs.

The generic ingredient in CARFILZOMIB is carfilzomib. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carfilzomib profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Carfilzomib

A generic version of CARFILZOMIB was approved as carfilzomib by DR REDDYS on September 9th, 2019.

  Try a Trial

Drug patent expirations by year for CARFILZOMIB
Recent Clinical Trials for CARFILZOMIB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Carl Ola Landgren, MD, PhDPhase 2
GlaxoSmithKlinePhase 2
Dong-A University HospitalPhase 2

See all CARFILZOMIB clinical trials

Paragraph IV (Patent) Challenges for CARFILZOMIB
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KYPROLIS For Injection carfilzomib 10 mg/vial 202714 1 2018-11-28
KYPROLIS For Injection carfilzomib 30 mg/vial 202714 1 2017-10-05
KYPROLIS For Injection carfilzomib 60 mg/vial 202714 9 2016-07-20

US Patents and Regulatory Information for CARFILZOMIB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex CARFILZOMIB carfilzomib POWDER;INTRAVENOUS 211185-001 Mar 20, 2020 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Breckenridge CARFILZOMIB carfilzomib POWDER;INTRAVENOUS 209330-002 Jun 11, 2021 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Apotex CARFILZOMIB carfilzomib POWDER;INTRAVENOUS 209425-001 Mar 16, 2020 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Breckenridge CARFILZOMIB carfilzomib POWDER;INTRAVENOUS 209330-001 Jun 11, 2021 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Dr Reddys CARFILZOMIB carfilzomib POWDER;INTRAVENOUS 209422-001 Sep 9, 2019 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for CARFILZOMIB

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Amgen Europe B.V. Kyprolis carfilzomib EMEA/H/C/003790
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Authorised no no yes 2015-11-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.